232 related articles for article (PubMed ID: 18482683)
1. Can celecoxib affect P-glycoprotein-mediated drug efflux? A microPET study.
de Vries EF; Doorduin J; Vellinga NA; van Waarde A; Dierckx RA; Klein HC
Nucl Med Biol; 2008 May; 35(4):459-66. PubMed ID: 18482683
[TBL] [Abstract][Full Text] [Related]
2. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier.
Hendrikse NH; de Vries EG; Eriks-Fluks L; van der Graaf WT; Hospers GA; Willemsen AT; Vaalburg W; Franssen EJ
Cancer Res; 1999 May; 59(10):2411-6. PubMed ID: 10344751
[TBL] [Abstract][Full Text] [Related]
3. In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier.
Hsiao P; Bui T; Ho RJ; Unadkat JD
Drug Metab Dispos; 2008 Mar; 36(3):481-4. PubMed ID: 18057117
[TBL] [Abstract][Full Text] [Related]
4. Lipid excipients Peceol and Gelucire 44/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells.
Sachs-Barrable K; Thamboo A; Lee SD; Wasan KM
J Pharm Pharm Sci; 2007; 10(3):319-31. PubMed ID: 17727795
[TBL] [Abstract][Full Text] [Related]
5. Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport.
Syvänen S; Lindhe O; Palner M; Kornum BR; Rahman O; Långström B; Knudsen GM; Hammarlund-Udenaes M
Drug Metab Dispos; 2009 Mar; 37(3):635-43. PubMed ID: 19047468
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of dopamine D3 receptor antagonist 11C-GR218231 as PET tracer for P-glycoprotein.
de Vries EF; Kortekaas R; van Waarde A; Dijkstra D; Elsinga PH; Vaalburg W
J Nucl Med; 2005 Aug; 46(8):1384-92. PubMed ID: 16085598
[TBL] [Abstract][Full Text] [Related]
7. Effect of P-glycoprotein-mediated efflux on cerebrospinal fluid concentrations in rhesus monkeys.
Tang C; Kuo Y; Pudvah NT; Ellis JD; Michener MS; Egbertson M; Graham SL; Cook JJ; Hochman JH; Prueksaritanont T
Biochem Pharmacol; 2009 Sep; 78(6):642-7. PubMed ID: 19481060
[TBL] [Abstract][Full Text] [Related]
8. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography.
Hendrikse NH; Schinkel AH; de Vries EG; Fluks E; Van der Graaf WT; Willemsen AT; Vaalburg W; Franssen EJ
Br J Pharmacol; 1998 Aug; 124(7):1413-8. PubMed ID: 9723952
[TBL] [Abstract][Full Text] [Related]
9. Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data.
Hsiao P; Sasongko L; Link JM; Mankoff DA; Muzi M; Collier AC; Unadkat JD
J Pharmacol Exp Ther; 2006 May; 317(2):704-10. PubMed ID: 16415090
[TBL] [Abstract][Full Text] [Related]
10. Existence of a p-glycoprotein drug efflux pump in cultured rabbit conjunctival epithelial cells.
Saha P; Yang JJ; Lee VH
Invest Ophthalmol Vis Sci; 1998 Jun; 39(7):1221-6. PubMed ID: 9620082
[TBL] [Abstract][Full Text] [Related]
11. In vivo evaluation of P-glycoprotein modulation of 8 PET radioligands used clinically.
Ishiwata K; Kawamura K; Yanai K; Hendrikse NH
J Nucl Med; 2007 Jan; 48(1):81-7. PubMed ID: 17204702
[TBL] [Abstract][Full Text] [Related]
12. Biodistribution, radiation dose estimates, and in vivo Pgp modulation studies of 18F-paclitaxel in nonhuman primates.
Kurdziel KA; Kiesewetter DO; Carson RE; Eckelman WC; Herscovitch P
J Nucl Med; 2003 Aug; 44(8):1330-9. PubMed ID: 12902425
[TBL] [Abstract][Full Text] [Related]
13. In vivo evaluation in rodents of [(123)I]-3-I-CO as a potential SPECT tracer for the serotonin 5-HT(2A) receptor.
Blanckaert PB; Burvenich I; Wyffels L; De Bruyne S; Moerman L; De Vos F
Nucl Med Biol; 2008 Nov; 35(8):861-7. PubMed ID: 19026947
[TBL] [Abstract][Full Text] [Related]
14. Characterization of cyclosporin A transport in cultured rabbit corneal epithelial cells: P-glycoprotein transport activity and binding to cyclophilin.
Kawazu K; Yamada K; Nakamura M; Ota A
Invest Ophthalmol Vis Sci; 1999 Jul; 40(8):1738-44. PubMed ID: 10393043
[TBL] [Abstract][Full Text] [Related]
15. Investigation of the influence of modulation of P-glycoprotein by a multiple dosing regimen of tamoxifen on the pharmacokinetics and toxicodynamics of doxorubicin.
Darvari R; Boroujerdi M
Cancer Chemother Pharmacol; 2005 Nov; 56(5):497-509. PubMed ID: 15937726
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of [(11)C]rofecoxib as PET tracer for cyclooxygenase 2 overexpression in rat models of inflammation.
de Vries EF; Doorduin J; Dierckx RA; van Waarde A
Nucl Med Biol; 2008 Jan; 35(1):35-42. PubMed ID: 18158941
[TBL] [Abstract][Full Text] [Related]
17. New positron emission tomography tracer [(11)C]carvedilol reveals P-glycoprotein modulation kinetics.
Bart J; Dijkers EC; Wegman TD; de Vries EG; van der Graaf WT; Groen HJ; Vaalburg W; Willemsen AT; Hendrikse NH
Br J Pharmacol; 2005 Aug; 145(8):1045-51. PubMed ID: 15951832
[TBL] [Abstract][Full Text] [Related]
18. Effect of a P-glycoprotein inhibitor, Cyclosporin A, on the disposition in rodent brain and blood of the 5-HT1A receptor radioligand, [11C](R)-(-)-RWAY.
Liow JS; Lu S; McCarron JA; Hong J; Musachio JL; Pike VW; Innis RB; Zoghbi SS
Synapse; 2007 Feb; 61(2):96-105. PubMed ID: 17117422
[TBL] [Abstract][Full Text] [Related]
19. Efficient sequential synthesis of PET Probes of the COX-2 inhibitor [11C]celecoxib and its major metabolite [11C]SC-62807 and in vivo PET evaluation.
Takashima-Hirano M; Takashima T; Katayama Y; Wada Y; Sugiyama Y; Watanabe Y; Doi H; Suzuki M
Bioorg Med Chem; 2011 May; 19(9):2997-3004. PubMed ID: 21482120
[TBL] [Abstract][Full Text] [Related]
20. Steady-state brain concentrations of antihistamines in rats: interplay of membrane permeability, P-glycoprotein efflux and plasma protein binding.
Mahar Doan KM; Wring SA; Shampine LJ; Jordan KH; Bishop JP; Kratz J; Yang E; Serabjit-Singh CJ; Adkison KK; Polli JW
Pharmacology; 2004 Oct; 72(2):92-8. PubMed ID: 15331914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
